Aura Biosciences price target raised to $24 from $21 at BTIG

BTIG raised the firm’s price target on Aura Biosciences (AURA) to $24 from $21 and keeps a Buy rating on the shares. The company’s early data from the ongoing Phase 1 NMIBC – non-muscle invasive bladder cancer – trial show bel-sar having a consistent abscopal effect with broad immune infiltrate, and the firm sees this benefit reading through positively to durable clinical remissions at later time points in future studies, the analyst tells investors in a research note. 70% to 80% of NMIBC patients experience recurrence with current standard of care, so there is a large unmet need and opportunity for differentiation, the firm added.